{"id":"air645","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AIR645 is designed as a locally-acting therapeutic delivered via inhalation to treat inflammatory airway diseases. The drug's specific molecular mechanism and target remain proprietary to Altair Therapeutics, but development has focused on respiratory indications where local lung delivery may provide therapeutic benefit with reduced systemic exposure.","oneSentence":"AIR645 is an inhaled biologic that targets airway inflammation through a mechanism involving immune modulation in the respiratory tract.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:21:20.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory airway disease (specific indication under investigation in Phase 2)"}]},"trialDetails":[{"nctId":"NCT00941577","phase":"PHASE2","title":"Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma","status":"COMPLETED","sponsor":"Altair Therapeutics, Inc.","startDate":"2009-10","conditions":"Asthma","enrollment":30},{"nctId":"NCT00658749","phase":"PHASE1","title":"A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma","status":"COMPLETED","sponsor":"Altair Therapeutics, Inc.","startDate":"2008-04","conditions":"Asthma","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AIR645","genericName":"AIR645","companyName":"Altair Therapeutics, Inc.","companyId":"altair-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AIR645 is an inhaled biologic that targets airway inflammation through a mechanism involving immune modulation in the respiratory tract. Used for Inflammatory airway disease (specific indication under investigation in Phase 2).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}